National Cancer Institute; Notice of Closed Meetings, 11364-11365 [2017-03388]
Download as PDF
11364
Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices
Time: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Ramesh Vemuri, Ph.D.,
Chief, Scientific Review Branch, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, 7201 Wisconsin
Avenue, Suite 2C–212, Bethesda, MD 20892,
301–402–7700, rv23r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: February 16, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03446 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Inhibition of host heme oxygenase-1
as an adjunctive treatment to improve
the outcome of conventional antibiotic
chemotherapy of Mycobacterium
tuberculosis (Mtb) infection.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Description of Technology
This invention describes the
adjunctive use of heme oxygenase-1
VerDate Sep<11>2014
16:05 Feb 21, 2017
Jkt 241001
(HO–1) inhibitors to improve the
outcome of conventional antibiotic
treatment for tuberculosis. The existent
standard of care requires prolonged
administration of drug. Due to the long
duration of treatment, methods that can
more rapidly control tuberculosis in
patients are clearly needed.
NIAID researchers have discovered
that inhibition of host HO–1 reduces
Mycobacterium tuberculosis (Mtb)
growth in vivo and, more importantly,
when used as an adjunct to
conventional chemotherapy, results in a
marked improvement in pulmonary
bacterial control. In particular, it was
found using a mouse model that HO–1
inhibitors enhance bacterial clearance
when used in conjunction with
conventional antibiotic therapy.
Further, no obvious toxic side effects
were found. Since this host-directed
strategy does not directly target the
pathogen itself, it may have an added
advantage as a treatment for infections
with antibiotic-resistant Mtb strains.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutic for Mtb.
Competitive Advantages:
• Innovative, more rapidly effective
therapeutics for tuberculosis are sorely
needed due to the continued importance
of TB as a global infectious disease and
the increasing emergence of multi-drug
resistant strains.
• This invention is a host-directed
therapy.
Development Stage: Pre-Clinical.
Inventors:
F. Alan Sher, NIAID, NIH
Diego L. Costa, NIAID, NIH
Bruno B. Andrade, NIAID, NIH
Publications: Costa, Diego L., et al.
‘‘Pharmacological Inhibition of Host
Heme Oxygenase-1 Suppresses
Mycobacterium tuberculosis Infection In
Vivo by a Mechanism Dependent on T
Lymphocytes.’’ mBio 7.5 (2016):
e01675–16.
Intellectual Property: HHS Reference
No. E–174–2016/0—U.S. Patent
Application No. 62/357,558, filed 07/
01/2016.
Licensing Contact: James M.
Robinson; James.Robinson4@nih.gov;
301–761–7542.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further evaluate HO–1 inhibitors in
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
treating human tuberculosis. For
collaboration opportunities, please
contact James M. Robinson;
James.Robinson4@nih.gov; 301–761–
7542.
Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03451 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Radiotherapy in Combination with Systemic
Agents.
Date: March 20, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W234, Bethesda, MD 20892–9750,
240–276–6368, Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Questions 12.
Date: March 23, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
E:\FR\FM\22FEN1.SGM
22FEN1
Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W634, Bethesda, MD
20892–9750, 240–276–5864, jennifer.schiltz@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; The
Chernobyl Tissue Bank—Coordinating
Center.
Date: May 2, 2017.
Time: 12:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH 9609 Medical Center Drive,
Room 7W234, Bethesda, MD 20892–9750,
240–276–6368, Stoicaa2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03388 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sradovich on DSK3GMQ082PROD with NOTICES
National Institute on Drug Abuse;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Drug Abuse Special Emphasis Panel,
February 17, 2017, 12:00 p.m. to
February 17, 2017, 05:00 p.m., National
Institutes of Health, Neuroscience
Center, 6001 Executive Boulevard,
Rockville, MD 20852 which was
published in the Federal Register on
January 25, 2017, 82 16 FR 2017–01737.
This meeting was amended to change
the date and time and will now be held
on March 29, 2017, from 10:30 a.m. to
12:30 p.m. The meeting is closed to the
public.
Dated: February 15, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03389 Filed 2–21–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:05 Feb 21, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR:
Psychiatric Disorders within the RDoc
Framework.
Date: March 6, 2017.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Julius Cinque, MS,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7846, Bethesda, MD 20892, (301) 435–
1252, cinquej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Health
Informatics Special Emphasis Panel.
Date: March 13, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Fairmount Hotel, 2401 M St. NW,
Washington, DC 20037.
Contact Person: Yvonne Owens Ferguson,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 3139,
Bethesda, MD 20892, 301–827–3689,
fergusonyo@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology, and Bioengineering.
Date: March 14–15, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Alexander Gubin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4196,
MSC 7812, Bethesda, MD 20892, 301–435–
2902, gubina@csr.nih.gov.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
11365
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Innovative
Immunology.
Date: March 14, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bahia Resort Hotel, 998 West
Mission Bay Drive, San Diego, CA 92109.
Contact Person: Andrea Keane-Myers,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
Bethesda, MD 20892, 3014351221,
andrea.keane-myers@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Biobehavioral Regulation and
Stress.
Date: March 14, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Biao Tian, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3089B, MSC 7848, Bethesda,
MD 20892, (301) 402–4411, tianbi@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Instrumentation, Environmental,
and Occupational Safety.
Date: March 16–17, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Kabuki, 1625 Post Street, San
Francisco, CA 94115.
Contact Person: Marie-Jose Belanger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm 6188 MSC
7804, Bethesda, MD 20892, 301–435–1267,
belangerm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Non-HIV Microbial Vaccines.
Date: March 16, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bahia Resort Hotel, 998 West
Mission Bay Drive, San Diego, CA 92109.
Contact Person: Andrea Keane-Myers,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
Bethesda, MD 20892, 301–435–1221,
andrea.keane-myers@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cardiovascular Sciences.
Date: March 16–17, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites by Hilton
Alexandria Old Town, 1900 Diagonal Road,
Alexandria, VA 22314.
Contact Person: Margaret Chandler, Ph.D.,
Scientific Review Officer, Center for
E:\FR\FM\22FEN1.SGM
22FEN1
Agencies
[Federal Register Volume 82, Number 34 (Wednesday, February 22, 2017)]
[Notices]
[Pages 11364-11365]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03388]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Radiotherapy in Combination with Systemic Agents.
Date: March 20, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W234, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Adriana Stoica, Ph.D., Scientific Review
Officer, Resources and Training Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W234, Bethesda, MD 20892-9750, 240-276-6368,
Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Provocative Questions 12.
Date: March 23, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W030, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Jennifer C. Schiltz, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
[[Page 11365]]
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W634, Bethesda, MD 20892-9750, 240-276-5864,
jennifer.schiltz@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; The Chernobyl Tissue Bank--Coordinating Center.
Date: May 2, 2017.
Time: 12:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W234, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Adriana Stoica, Ph.D., Scientific Review
Officer, Resources and Training Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH 9609 Medical
Center Drive, Room 7W234, Bethesda, MD 20892-9750, 240-276-6368,
Stoicaa2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03388 Filed 2-21-17; 8:45 am]
BILLING CODE 4140-01-P